The recognition of GAT inhibitors to exhibit anticonvulsant properties then led to the development of the GAT1 inhibitor tiagabine (11, vide infra) [21–23], which is currently the only approved GAT1 inhibitor that is clinically used for the adjunctive treatment of epilepsy [24]. This evidence concerns the gene SLC6A1 and epilepsy.